查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597833

T 細胞免疫療法市場：依作用機制、產品類別、治療類型、適應症分類 - 2025-2030 年全球預測

T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

T細胞免疫治療市場2023年估值為68.1億美元，預計2024年將達到77.4億美元，複合年成長率為14.12%，預計到2030年將達到171.7億美元。

T細胞免疫療法是癌症治療的一種創新方法，重點是增強人體的免疫系統來對抗疾病。該方法涉及修改 T 細胞以有效識別和破壞癌細胞。由於化療和放射線治療等傳統癌症治療的限制和副作用，出現了對這種治療的需求。這種治療方法主要應用於血癌，但隨著最近的技術創新，它也被應用於固體癌。主要最終使用者包括醫院、癌症治療中心和研究機構。癌症發病率的增加、基因編輯技術的進步以及 CAR-T 和 TCR-T 等治療方法的成功推動了市場成長。政府和私人組織的財政支持也刺激了市場動態。新的機會在於同種異體療法的開發，這些療法有望降低成本並增加可及性。與生技公司的合作夥伴關係和研究合作可以幫助您創新並提高治療方法效果，為您帶來競爭優勢。然而，高處理成本、複雜的製造流程和嚴格的監管要求等挑戰可能會阻礙成長。此外，後勤方面的挑戰，例如需要個人化治療，也是一個主要限制。為了克服這些障礙，重要的是提高製造技術並專注於具有成本效益的方法。人們越來越需要透過研究來了解腫瘤微環境並提高 T 細胞特異性以減少意外的副作用。該市場充滿活力，其特點是快速的技術創新、激烈的競爭和不斷變化的監管環境。最佳創新領域包括開發針對更廣泛腫瘤的下一代 T 細胞療法以及提高現有療法的安全性。透過專注於這些領域，公司可以抓住機會推進 T 細胞免疫療法，並在這個快速發展的市場中實現顯著成長和成功。

主要市場統計
基準年[2023] 68.1億美元
預測年份 [2024] 77.4億美元
預測年份 [2030] 171.7億美元
複合年成長率（%） 14.12%

市場動態：揭示快速發展的 T 細胞免疫治療市場的關鍵市場洞察

T 細胞免疫治療市場正因供需的動態交互作用而發生轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 癌症和自體免疫疾病的盛行率增加
    • 利用基於細胞的標靶治療
    • 增加支持 T 細胞免疫療法的研究和開發
  • 市場限制因素
    • 治療費用上漲
  • 市場機會
    • 製藥公司的商業化和資金籌措
    • 現成藥品的吸引力
  • 市場挑戰
    • 神經毒性和細胞激素釋放症候群

波特五力：駕馭 T 細胞免疫療法市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 T 細胞免疫治療市場的外部影響

外部宏觀環境因素在塑造 T 細胞免疫治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解T細胞免疫治療市場的競爭格局

T 細胞免疫治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣T細胞免疫治療市場供應商績效評估

FPNV定位矩陣是評估T細胞免疫療法市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了 T 細胞免疫治療市場的成功之路

T 細胞免疫治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症和自體免疫疾病的增加
      • 使用基於細胞的標靶治療
      • 在研發支持下增強 T 細胞免疫療法
    • 抑制因素
      • 治療費用上漲
    • 機會
      • 製藥公司的商業化和資金籌措
      • 現有治療方法的吸引力
    • 任務
      • 神經毒性和細胞激素釋放症候群
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依作用機轉分類的 T 細胞免疫治療市場

  • 主動免疫治療
  • 被動免疫療法

第7章 T 細胞免疫治療市場（依產品類別）

  • 雙特異性抗體
  • 細胞激素
  • 單株抗體
  • 溶瘤病毒療法

第8章 按治療類型分類的 T 細胞免疫治療市場

  • CAR-T
  • TCR
  • TIL

第9章 T 細胞免疫治療市場（按適應症）

  • B細胞惡性
  • 肝癌
  • 攝護腺癌
  • 腎臟細胞癌

第10章美洲T細胞免疫治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太T細胞免疫治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲T細胞免疫治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Adaptimmune Therapeutics PLC
  • Alaunos Therapeutics, Inc.
  • Apac Biotech
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Holdings Limited
  • Cellectis SA
  • Chimera Bioengineering
  • Dendreon Pharmaceuticals LLC
  • Eureka Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Green Cross Corporation
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics, Inc.
  • LAVA Therapeutics NV
  • Lyell Immunopharma, Inc.
  • Neogene Therapeutics, Inc.
  • NeoTX Therapeutics Ltd.
  • Novartis AG
  • Oxford Vacmedix UK Limited
  • Poseida Therapeutics, Inc.
  • TScan Therapeutics, Inc.
  • Xenetic Biosciences, Inc.
Product Code: MRR-034B5003094B

The T-Cell Immunotherapy Market was valued at USD 6.81 billion in 2023, expected to reach USD 7.74 billion in 2024, and is projected to grow at a CAGR of 14.12%, to USD 17.17 billion by 2030.

T-cell immunotherapy is a transformative approach in cancer treatment, focusing on enhancing the body's immune system to combat diseases. This method involves modifying T-cells to identify and destroy cancer cells efficiently. The necessity of this therapy arises due to the limitations and adverse effects of traditional cancer treatments like chemotherapy and radiation. Its application predominantly spans hematologic cancers, though recent innovations are expanding its use to solid tumors as well. Key end-users include hospitals, cancer treatment centers, and research institutes. Market growth is propelled by increasing cancer incidences, advancements in gene-editing technologies, and the success of therapies like CAR-T and TCR-T. Funding from government and private entities also stimulates market dynamics. Emerging opportunities lie in the development of allogeneic therapies, which promise reduced costs and enhanced accessibility. Collaborations and partnerships with biotech firms to innovate and enhance therapy efficacy can provide a competitive edge. However, challenges such as high treatment costs, complexities in manufacturing processes, and stringent regulatory requirements can hinder growth. Additionally, logistical challenges, including the need for personalized treatment, also pose significant constraints. To overcome these obstacles, enhancing production technologies and focusing on cost-effective methods are crucial. There is a growing need for research in understanding tumor microenvironments and improving the specificity of T-cells to reduce unintended side effects. The market exudes a dynamic nature, characterized by rapid technological innovations, intense competition, and evolving regulatory landscapes. The best areas of innovation include developing next-generation T-cell therapies that can target a wider range of tumors and enhancing the safety profiles of existing therapies. By focusing on these areas, companies can seize opportunities to advance T-cell immunotherapy and enjoy significant growth and success in this rapidly evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 6.81 billion
Estimated Year [2024] USD 7.74 billion
Forecast Year [2030] USD 17.17 billion
CAGR (%) 14.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving T-Cell Immunotherapy Market

The T-Cell Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence of Cancer and Autoimmune Diseases
    • Use of Cell-Based Targeted Therapies
    • Increasing R&D Supporting T-cell Immunotherapy
  • Market Restraints
    • High Cost of Treatment
  • Market Opportunities
    • Commercialisation and Funding by Pharmaceutical Companies
    • Attractiveness of Off-the-Shelf Therapies
  • Market Challenges
    • Neurologic Toxicities and Cytokine Release Syndrome

Porter's Five Forces: A Strategic Tool for Navigating the T-Cell Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the T-Cell Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the T-Cell Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the T-Cell Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the T-Cell Immunotherapy Market

A detailed market share analysis in the T-Cell Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the T-Cell Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the T-Cell Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the T-Cell Immunotherapy Market

A strategic analysis of the T-Cell Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Alaunos Therapeutics, Inc., Apac Biotech, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., LAVA Therapeutics N.V., Lyell Immunopharma, Inc., Neogene Therapeutics, Inc., NeoTX Therapeutics Ltd., Novartis AG, Oxford Vacmedix UK Limited, Poseida Therapeutics, Inc., TScan Therapeutics, Inc., and Xenetic Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the T-Cell Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mechanism Of Action, market is studied across Active Immunotherapy and Passive Immunotherapy.
  • Based on Product Class, market is studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.
  • Based on Type of Therapy, market is studied across CAR-T, TCR, and TIL.
  • Based on Indication, market is studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
      • 5.1.1.2. Use of Cell-Based Targeted Therapies
      • 5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost of Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
      • 5.1.3.2. Attractiveness of Off-the-Shelf Therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. T-Cell Immunotherapy Market, by Mechanism Of Action

  • 6.1. Introduction
  • 6.2. Active Immunotherapy
  • 6.3. Passive Immunotherapy

7. T-Cell Immunotherapy Market, by Product Class

  • 7.1. Introduction
  • 7.2. Bispecific Antibodies
  • 7.3. Cytokines
  • 7.4. Monoclonal Antibodies
  • 7.5. Oncolytic Virus Therapy

8. T-Cell Immunotherapy Market, by Type of Therapy

  • 8.1. Introduction
  • 8.2. CAR-T
  • 8.3. TCR
  • 8.4. TIL

9. T-Cell Immunotherapy Market, by Indication

  • 9.1. Introduction
  • 9.2. B-cell Malignancies
  • 9.3. Liver Cancer
  • 9.4. Prostate Cancer
  • 9.5. Renal Cell Carcinoma

10. Americas T-Cell Immunotherapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific T-Cell Immunotherapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa T-Cell Immunotherapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptimmune Therapeutics PLC
  • 2. Alaunos Therapeutics, Inc.
  • 3. Apac Biotech
  • 4. Atara Biotherapeutics, Inc.
  • 5. Autolus Therapeutics PLC
  • 6. bluebird bio, Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. CARsgen Therapeutics Holdings Limited
  • 9. Cellectis SA
  • 10. Chimera Bioengineering
  • 11. Dendreon Pharmaceuticals LLC
  • 12. Eureka Therapeutics, Inc.
  • 13. Gilead Sciences, Inc.
  • 14. Green Cross Corporation
  • 15. Innovative Cellular Therapeutics
  • 16. Iovance Biotherapeutics, Inc.
  • 17. LAVA Therapeutics N.V.
  • 18. Lyell Immunopharma, Inc.
  • 19. Neogene Therapeutics, Inc.
  • 20. NeoTX Therapeutics Ltd.
  • 21. Novartis AG
  • 22. Oxford Vacmedix UK Limited
  • 23. Poseida Therapeutics, Inc.
  • 24. TScan Therapeutics, Inc.
  • 25. Xenetic Biosciences, Inc.

LIST OF FIGURES

  • FIGURE 1. T-CELL IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. T-CELL IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. T-CELL IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. T-CELL IMMUNOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023